Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
Abstract Some recent studies have suggested that the use of dipeptidyl peptidase-4 inhibitors (DPP4i) is associated with cancer development. However, some other studies suggest no such association. The aim of the present study was to evaluate the effect of DPP4i on the risk of developing cancers. Th...
Guardado en:
Autores principales: | Ming Zhao, Jiayi Chen, Yanyan Yuan, Zuquan Zou, Xiaolong Lai, Daud M Rahmani, Fuyan Wang, Yang Xi, Qin Huang, Shizhong Bu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d65c9a48207b4b24bfd98f68dab00c09 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
por: Lana C. Pinto, et al.
Publicado: (2018) -
Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
por: Taras S. Panevin, et al.
Publicado: (2020) -
Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Wang N, et al.
Publicado: (2019) -
Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose
por: Das SS, et al.
Publicado: (2014) -
Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin YH, et al.
Publicado: (2019)